The Event

Swiss Biotech Day 2026

Related News

Adcendo ApS Announces Phase 1 Clinical Data Showing Compelling Safety & Antitumor Activity with ADCE-D01 in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Favorable safety and tolerability profile with very few patients needing dose reduction

Inbiomotion’s MAF Test® now available to early-stage breast cancer patients in the United States through NeoGenomics

Could benefit an estimated 258,000 newly diagnosed patients annually.

NorthSea Therapeutics Announces Positive Phase 2 Topline Data in First-ever Randomized Placebo-controlled Study of an Oral Therapy in Intestinal Failure-Associated Liver Disease

Orziloben-treated patients saw rapid and sustained improvements in cholestatic liver injury.